Growth Stocks First Half: Two Big Picks for 2026 Market
As volatility remains a theme, smart investors are looking for growth stocks first half opportunities with real catal...
Volatile Periods Retirees Should Expect Sp 500
This article outlines typical volatile periods for SP 500 and how retirees can position portfolios to endure drawdowns while meeting needs.
26,423 articlesArtificial Intelligence Stocks Hold: 3 Picks for a Decade
AI is reshaping business models across industries. Here are three AI stocks you can buy and hold for the long term, w...
Merck Price Prediction: Sac-TMT Could Lift MRK to Peak
Analysts are arguing that Merck's sac-TMT program could unlock substantial upside for MRK, supported by a strong pipe...
XRP Price Prediction: Can XRP Reach $100? Analysts Speak
As XRP fluctuates in a tight range, traders and analysts scrutinize whether the price prediction: reach $100? is conc...
Rumble (RUM) 2025 Earnings: Growth, Risks, Outlook
Rumble's Q4 2025 results point to a shift from rapid growth to sustainable profitability. This article breaks down re...
History Covering This Stock: A Bold Buy Signal Emerges Now
After years of watching this stock trade at lofty valuations, a broad market sell-off finally creates an entry point....
Argus Upgrades Palantir to Buy After Sell-Off: Is $190 Floor?
Palantir surged into focus after blowout Q1 results and a fresh Buy rating from Argus with a $190 target, raising que...
Owlet (OWLT) 2026 Earnings Outlook for Investors and Growth
Owlet's Q1 2026 earnings provide a window into revenue drivers, margins, and strategic pivots. This guide breaks down...
This Stock Could Easiest 10x Trade in 2026 for AI Bulls
A niche AI hardware stock is drawing investors as hyperscale data centers surge. Analysts say this stock could easies...
Scott Bessent Made Fortune: Yuan, Markets and Europe
In a year of currency flux, veteran trader Scott Bessent's history of bold bets sheds light on Beijing's yuan policy ...
Erasca Stock 715%. Here’s Why One Biotech Fund Still Bets More
A major biotech fund boosted its Erasca stake after a monumental rise. This article unpacks the logic, risks, and tak...
UBS Upgrades Jazz Pharmaceuticals to Buy, Sets $307 Target
UBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
Popular Topics
Fable
Smart Money Moves For Everyday Life
Investment Strategies In Energy Sector
Best Index Funds For Retirement
Investment Strategies
Untitled D6eff7ea
Crypto For Beginners
Best Dividend Etfs
Index
Innovative Skincare Clinical
Dutch Salary
Blue Owl
Budget
Ai Healthcare News
Penalty Vs No Penalty Depending On Lock Status